Our Mission

Aleta’s mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aleta’s CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2023.

Our Science

With our CAR-T Engager platform, we are building treatments to enhance cell therapies. Our lead candidate, ALETA-001, is focused on eliminating CD19 CAR-T relapses.

Latest News

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

ALETA-001 Was Developed to Address the Urgent Unmet Need of Patient Relapse After CD19-Targeted CAR T-Cell Cancer Treatment. Click the link above to read all about it.

CAR T Engager proteins optimize anti CD19 CAR T cell therapies for lymphoma

Aleta’s -001 preclinical development paper has been published. This takes Aleta from MOA and efficacy through dose estimation, PK and early protein CMC. Click the link above to read all about it.

Aleta Biotherapeutics Announces Presentation at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today released new preclinical results at the 25th American Society of Gene & Cell Therapy Annual Meeting, held in Washington DC and in a virtual platform on May 16-19, 2022. ASGCT is the premier showcase for advances in cell and gene engineering, development and clinical translation.

The presentation featured preclinical data that advance Aleta’s programs in development for the treatment of multiple myeloma and acute myeloid leukemia. These programs leverage the company’s proprietary CAR T Engager technology – multi-antigen targeting systems designed to expand the functionality of conventional cell therapeutics.

Get In Touch

Send message